Selank: Benefits, Anxiolytic Mechanism, and Research Status (2026)
Most claims about Selank benefits come from a small, mostly Russian body of research, not from large Western trials. Selank is a synthetic heptapeptide built from tuftsin, a natural immune-signaling fragment, and it has been studied mainly as an anxiolytic (anti-anxiety) and nootropic compound. The honest summary is that the early data is interesting and the human evidence is thin.
The Compound Universe Take: Selank is a tuftsin-derived peptide studied for anxiety, stress, and cognition. In Russian clinical work its anti-anxiety effect looked comparable to low-dose benzodiazepines but without sedation or dependence, while its cognitive and BDNF-related effects rest largely on animal studies. It is not FDA-approved and is sold for research use only, so treat it as research-stage, not proven therapy.
New here? See the other peptides researched for anxiety for the wider category, then use this page for the compound-specific detail.
What Selank is (a tuftsin analog heptapeptide)
Selank is a synthetic seven-amino-acid peptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro). It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a stable analog of tuftsin, an endogenous tetrapeptide with immune-modulating activity.
The design goal was metabolic stability. Natural tuftsin breaks down quickly, so the added residues let Selank act longer while keeping tuftsin-like signaling.
Because it descends from an immune peptide, Selank sits at an unusual crossover: it is discussed as an anxiolytic, a nootropic, and an immunomodulator at the same time. That breadth is part of why it is hard to summarize cleanly.
| Attribute | Detail |
|---|---|
| Class | Synthetic heptapeptide (tuftsin analog) |
| Most studied for | Anxiety, stress, cognition, immune signaling |
| Evidence tier | Human pilot (Russian) + animal; no Western RCT |
| Legal status (US) | Not FDA-approved; research use only; 503A Category 2 |
How Selank works: GABA, enkephalins, and BDNF
Selank does not appear to have one single mechanism. Research points to several overlapping routes rather than a clean drug-receptor story.
The GABA link is the most cited. A gene-expression study in rats found that Selank changed the messenger-RNA levels of dozens of genes tied to GABAergic neurotransmission, overlapping partly with the pattern produced by GABA itself (Animal / in-vivo) [3]. The authors read this as allosteric modulation of the GABA system rather than direct receptor binding.
A second route involves the body’s own enkephalins. In the human anxiety trial below, Selank was associated with slower breakdown of leu-enkephalin in serum, and that change tracked with symptom improvement (Human pilot) [1].
A third route is neurotrophic. In rats, Selank altered brain-derived neurotrophic factor (BDNF) content in the hippocampus and prefrontal cortex, which researchers connect to its cognitive and memory effects (Animal) [4].
Selank benefits reported in the research (evidence-tiered)
Here is where the claims meet the sources. Each is labeled by the strongest evidence that actually exists, not by how it is marketed.
Anxiety: human pilot data against a benzodiazepine
The most quoted human study enrolled 62 patients with generalized anxiety disorder and neurasthenia, comparing intranasal Selank against the benzodiazepine medazepam over two weeks (Zozulya and colleagues, 2008). The anti-anxiety effect of the two was similar, and Selank additionally showed antiasthenic (anti-fatigue) and mild psychostimulant effects (Human pilot) [1].
That is meaningful but limited. The trial was small, open in design, and has not been replicated in a large Western randomized controlled trial. It supports “promising,” not “proven.”
Cognition, memory, and BDNF: animal evidence
The nootropic reputation is mostly preclinical. In one rat model, Selank produced a cognition-stimulating effect and prevented memory and attention disturbances tied to chronic alcohol exposure, alongside changes in BDNF in the hippocampus and frontal cortex (Animal) [4].
Human cognitive-performance trials at this level of rigor are not available, so the “focus and clarity” claims should be read as extrapolation from animals plus the anti-fatigue signal seen in the anxiety trial.
Stress resilience and combination effects
In a chronic-stress rat model, Selank combined with diazepam reduced anxiety more than either compound alone under unpredictable mild stress (Animal) [2]. This hints at a complementary mechanism, but combining compounds in animals does not translate into a human protocol, and this page does not suggest one.
Legal and research-use-only status of Selank
Selank has never been approved by the FDA for any use. It has no USP monograph and is not an ingredient in any FDA-approved drug.
In the United States it is treated as a 503A Category 2 bulk substance, meaning it falls outside FDA enforcement discretion for pharmacy compounding (Regulatory) [5]. In practice it is sold labeled “for research use only,” and its status can change as regulators review peptide compounding.
Read this before the hype: Selank is not FDA-approved and is sold for research use only. This article summarizes published research; it is not medical advice, a dosing guide, or an endorsement of use. Legal status varies by jurisdiction and is changing.
| Reported effect | Proposed mechanism | Evidence tier | Status |
|---|---|---|---|
| Reduced anxiety | GABAergic + enkephalin modulation | Human pilot (Russian) | Not FDA-approved |
| Anti-fatigue / antiasthenic | Enkephalin, monoamine signaling | Human pilot | Not FDA-approved |
| Memory / cognition | BDNF regulation | Animal | Research use only |
| Stress resilience | GABA system, synergy with diazepam | Animal | Research use only |
Key takeaways
- Selank is a tuftsin-derived heptapeptide studied as an anxiolytic and nootropic, not an approved medicine [1].
- Its clearest human signal is anti-anxiety activity comparable to a benzodiazepine in one small trial, without the sedation [1].
- The cognitive and BDNF-related benefits are animal-stage, so “focus” claims run ahead of human proof [4].
- Proposed mechanisms center on GABAergic modulation and enkephalin metabolism rather than one receptor [3].
- Selank is not FDA-approved and is sold for research use only, with an evolving legal status [5].
Frequently asked questions
What are the main Selank benefits studied so far?
Research points to reduced anxiety, an anti-fatigue effect, and possible cognitive support. The anxiety evidence is human pilot level, while the cognitive evidence is mostly from animals.
Is Selank FDA-approved?
No. Selank has no FDA approval and no USP monograph, and it is treated as a 503A Category 2 bulk substance in the United States. It is sold labeled for research use only.
How is Selank thought to work?
It appears to modulate the GABA system allosterically, slow the breakdown of the body’s enkephalins, and influence BDNF. These are proposed, overlapping routes rather than one confirmed mechanism.
Is Selank a benzodiazepine?
No. Selank is a peptide, not a benzodiazepine, though one small trial found its anti-anxiety effect was similar to the benzodiazepine medazepam, reportedly without sedation or dependence.
What is the difference between Selank and Semax?
Both are Russian-developed peptides, but Semax is studied more for cognition and neuroprotection while Selank is framed around anxiety and stress. See the Selank vs Semax comparison for the side-by-side detail.
Is there strong human evidence for Selank?
Not yet. The main human data comes from small Russian studies; no large Western randomized controlled trial has confirmed the effects, so it remains research-stage.
Selank, the synthetic tuftsin analog developed at the Institute of Molecular Genetics, sits where anxiolytic, nootropic, and immunomodulatory research overlap, acting through GABAergic modulation, enkephalin metabolism, and BDNF regulation while its closest peptide relatives, Semax and other regulatory heptapeptides, share the same Russian research lineage; Compound Universe tracks each of these compounds against the primary literature so the picture reflects evidence maturity rather than marketing momentum.
The bottom line on Selank benefits is measured optimism: a peptide with a credible anti-anxiety signal in small human studies and promising animal data for cognition, held back by the absence of large controlled trials and by research-use-only legal status. Read it as an active research subject, not a settled therapy. For the compound-level picture, review the Selank vs Semax comparison, and check how Compound Universe tracks peptide legality before relying on any status claim.
References
- Zozulia AA, Neznamov GG, Siuniakov TS, Kost NV, Gabaeva MV, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova. 2008. PMID 18454096.
- Kasian A, Kolomin T, Andreeva L, Bondarenko E, Myasoedov N, Slominsky P, Shadrina M. Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats. Behavioural Neurology. 2017. PMID 28280289 / PMC5322660.
- Volkova A, Shadrina M, Kolomin T, Andreeva L, Limborska S, Myasoedov N, Slominsky P. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Frontiers in Pharmacology. 2016. DOI 10.3389/fphar.2016.00031.
- Kolik LG, et al. Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats. Bulletin of Experimental Biology and Medicine. 2019. PMID 31625062 / DOI 10.1007/s10517-019-04588-9.
- U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (Selank classified Category 2). fda.gov.